arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Veradermics, Inc

MANE
$114.40 ▲ +5.86 (+5.40%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
3 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
89
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Veradermics, Inc shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $85.2M
Dividend Yield
Revenue Growth
Op. Margin
ROIC 59.8%
FCF / Share $-96.14
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

3-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-70.00M
↓ -164.3%
FCF / Share Free cash flow per share
$-96.14
↓ -199.1%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
97
Cash Quality
67

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 3 years · 5 quarters